Background Pathogenic mutations in genes encoding components of the Ras/mitogen-activated protein kinase (Ras-MAPK) pathway cause RASopathy. Here, we describe five unrelated patients with SLE carrying ...

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead ...

Panel A summarizes the conventional model of how oncogenic RAS ... kinase (ERK). AF6 denotes afadin, GAP GTPase-activating protein, GEF guanine exchange factor, MEK mitogen-activated protein ...

induce a pressor response by activating the p38 mitogen-activated protein kinase (p38 MAPK) and extracellular signal-regulated kinase (ERK) pathway. The small G protein Ras mediates a ...

For many years, the Ras signaling ... ERK1 and ERK2 MAP kinases: specific roles or functional redundancy? Front Cell Dev Biol. 2016;4. doi: 10.3389/fcell.2016.00053 7. Yoon S, Seger R. The ...

primarily KIT and K-RAS. The receptor Tyrosine Kinase (RTK) pathway and the downstream related Mitogen-Activated Protein Kinase (MAPK) cascades are crucial signal transduction pathways that preside ...

Copyright: © 2005 Elsevier Ltd. Published by Elsevier Ltd. There are three major subfamilies of mitogen-activated protein kinases (MAPK): the extracellular-signal ...

Hyperactivation of the RAS-RAF-MEK-ERK cascade - a mitogen-activated protein kinase pathway – has a well-known association with oncogenesis of leading tumor entities, including non-small cell lung ...

SHP2 is upstream of KRAS and referees cellular signaling through the RAS/MAP kinase pathway; it's often overactive in various types of cancer. KRAS G12C inhibition and SHP2 inhibition have ...